A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...
A previous randomized study found improvements in reported quality of life among cancer patients whose neuropathy was linked ... adoption of the Quell Fibromyalgia solution,” said electroCore ...
It treats fibromyalgia symptoms and lower-extremity chronic pain. The company also offers DPNCheck, a point-of-care screening test for peripheral neuropathy. However, ElectroCore said it expects ...
TNX-102 SL was granted Fast Track designation for fibromyalgia by the FDA in July of 2024. Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill ...
Fibromyalgia is a common chronic pain disorder that is understood to result from ... post-concussive syndrome (also known as mild traumatic brain injury), chronic Lyme Disease, chronic diabetic ...
TNX-102 SL is a non-opioid, centrally-acting analgesic administered at bedtime for the treatment of fibromyalgia. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA ...
A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle degeneration. Researchers have discovered that an experimental compound ...